Jana McHugh, MB Bch BAO (Hons), MRCPI, FFR, presented “PROFILE Study: Early Data on Targeted Screening for Prostate Cancer in Men of African and African Caribbean Ancestry” during the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 21, 2023.
How to cite: McHugh, Jana. “PROFILE Study: Early Data on Targeted Screening for Prostate Cancer in Men of African and African Caribbean Ancestry.” September 21, 2023. Accessed May 2024. https://grandroundsinurology.com/profile-study-early-data-on-targeted-screening-for-prostate-cancer-in-men-of-african-and-african-caribbean-ancestry/
PROFILE Study: Early Data on Targeted Screening for Prostate Cancer in Men of African and African Caribbean Ancestry – Summary
Jana McHugh, MB Bch BAO (Hons), MRCPI, FFR, presents the results from the ongoing PROFILE study, a multi-cohort study of targeted screening for groups of men at higher risk of developing prostate cancer. Specifically, Dr. McHugh presents the early results of PROFILE’s second cohort: Men of African and African Caribbean ancestry aged 40-69. Dr. McHugh begins by providing an overview of the design of the PROFILE study, explaining the criteria for inclusion in the study, the PSA-dependent and PSA-independent arms of the study, and treatment options for prostate cancer patients.
Dr. McHugh then turns to the role of polygenic risk scores in prostate cancer screening, focusing on genetic risk scores and ancestry. She notes that prostate cancer was detected in 39% of the PROFILE study’s second cohort thus far, and highlights the need for further exploration into the role of genetic risk score in prostate cancer screening.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
